PURPOSE: Osteosarcoma and atypical teratoid rhabdoid tumors are tumor entities with varying response to common standard therapy protocols. Histone acetylation affects chromatin structure and gene expression which are considered to influence radiation sensitivity. The aim of this study was to investigate the effect of the combination therapy with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and irradiation on atypical teratoid rhabdoid tumors and osteosarcoma compared to normal tissue cell lines. METHODS: Clonogenic assay was used to determine cell survival. DNA double-strand breaks (DSB) were examined by pulsed-field electrophoresis (PFGE) as well as by γH2AX immunostaining involving flow cytometry, fluorescence microscopy, and immunoblot analysis. RESULTS: SAHA lead to an increased radiosensitivity in tumor but not in normal tissue cell lines. γH2AX expression as an indicator for DSB was significantly increased when SAHA was applied 24 h before irradiation to the sarcoma cell cultures. In contrast, γH2AX expression in the normal tissue cell lines was significantly reduced when irradiation was combined with SAHA. Analysis of initial DNA fragmentation and fragment rejoining by PFGE, however, did not reveal differences in response to the SAHA pretreatment for either cell type. CONCLUSION: SAHA increases radiosensitivity in tumor but not normal tissue cell lines. The increased H2AX phosphorylation status of the SAHA-treated tumor cells post irradiation likely reflects its delayed dephosphorylation within the DNA damage signal decay rather than chromatin acetylation-dependent differences in the overall efficacy of DSB induction and rejoining. The results support the hypothesis that combining SAHA with irradiation may provide a promising strategy in the treatment of solid tumors.
PURPOSE:Osteosarcoma and atypical teratoid rhabdoid tumors are tumor entities with varying response to common standard therapy protocols. Histone acetylation affects chromatin structure and gene expression which are considered to influence radiation sensitivity. The aim of this study was to investigate the effect of the combination therapy with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and irradiation on atypical teratoid rhabdoid tumors and osteosarcoma compared to normal tissue cell lines. METHODS: Clonogenic assay was used to determine cell survival. DNA double-strand breaks (DSB) were examined by pulsed-field electrophoresis (PFGE) as well as by γH2AX immunostaining involving flow cytometry, fluorescence microscopy, and immunoblot analysis. RESULTS:SAHA lead to an increased radiosensitivity in tumor but not in normal tissue cell lines. γH2AX expression as an indicator for DSB was significantly increased when SAHA was applied 24 h before irradiation to the sarcoma cell cultures. In contrast, γH2AX expression in the normal tissue cell lines was significantly reduced when irradiation was combined with SAHA. Analysis of initial DNA fragmentation and fragment rejoining by PFGE, however, did not reveal differences in response to the SAHA pretreatment for either cell type. CONCLUSION:SAHA increases radiosensitivity in tumor but not normal tissue cell lines. The increased H2AX phosphorylation status of the SAHA-treated tumor cells post irradiation likely reflects its delayed dephosphorylation within the DNA damage signal decay rather than chromatin acetylation-dependent differences in the overall efficacy of DSB induction and rejoining. The results support the hypothesis that combining SAHA with irradiation may provide a promising strategy in the treatment of solid tumors.
Authors: Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: Hendrik Andreas Wolff; Steffen Hennies; Markus Karl Alfred Herrmann; Margret Rave-Fränk; David Eickelmann; Patricia Virsik; Klaus Jung; Markus Schirmer; Michael Ghadimi; Clemens Friedrich Hess; Robert Michael Hermann; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-12-23 Impact factor: 3.621
Authors: Kevin Camphausen; William Burgan; Michael Cerra; Kelli A Oswald; Jane B Trepel; Min-Jung Lee; Philip J Tofilon Journal: Cancer Res Date: 2004-01-01 Impact factor: 12.701
Authors: Andrew Baschnagel; Andrea Russo; William E Burgan; Donna Carter; Katie Beam; Diane Palmieri; Patricia S Steeg; Philip Tofilon; Kevin Camphausen Journal: Mol Cancer Ther Date: 2009-06-09 Impact factor: 6.261
Authors: C Blattmann; M Thiemann; A Stenzinger; A Christmann; E Roth; V Ehemann; J Debus; A E Kulozik; W Weichert; P E Huber; S Oertel; A Abdollahi Journal: Strahlenther Onkol Date: 2013-06-27 Impact factor: 3.621
Authors: Claudia Blattmann; Markus Thiemann; Albrecht Stenzinger; Eva K Roth; Anne Dittmar; Hendrik Witt; Burkhard Lehner; Eva Renker; Manfred Jugold; Viktoria Eichwald; Wilko Weichert; Peter E Huber; Andreas E Kulozik Journal: J Transl Med Date: 2015-04-30 Impact factor: 5.531
Authors: Corina Penterling; Guido A Drexler; Claudia Böhland; Ramona Stamp; Christina Wilke; Herbert Braselmann; Randolph B Caldwell; Judith Reindl; Stefanie Girst; Christoph Greubel; Christian Siebenwirth; Wael Y Mansour; Kerstin Borgmann; Günther Dollinger; Kristian Unger; Anna A Friedl Journal: PLoS One Date: 2016-06-02 Impact factor: 3.240